Glucagon-Like Peptide-1 Receptor Agonist Treatment and Risk of Esophageal Cancer
Standard GLP-1RA treatment in patients with type 2 diabetes might not decrease the risk of esophageal adenocarcinoma. The validity of the observed decreased risk of esophageal squamous cell carcinoma is uncertain.
Authors
- Helgi Birgisson (ORCID: https://orcid.org/0000-0002-8246-6159)
- Giola Santoni (ORCID: https://orcid.org/0000-0002-9094-5037)
- Johan Hardvik Åkerström (ORCID: https://orcid.org/0000-0003-2199-7965)
- Joonas H. Kauppila (ORCID: https://orcid.org/0000-0001-6740-3726)
- Dag Holmberg (ORCID: https://orcid.org/0000-0003-1000-5422)
- Jesper Lagergren (ORCID: https://orcid.org/0000-0002-5143-5448)
- My von Euler‐Chelpin (ORCID: https://orcid.org/0000-0003-2204-7048)
- Eivind Ness‐Jensen (ORCID: https://orcid.org/0000-0001-6005-0729)
Institutions
- University of Copenhagen (DK)
- Karolinska University Hospital (SE)
- King's College London (GB)
- Norwegian University of Science and Technology (NO)
- Oulu University Hospital (FI)
- Levanger Hospital (NO)
- Karolinska Institutet (SE)
- Icelandic Cancer Society (IS)
- University of Oulu (FI)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.14309/ajg.0000000000003885
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29